Administer delivered a clear profitability beat in Q4 despite continued top-line headwinds.
Solwers reported its results for Q4 with sales of EUR 20.
Yesterday evening, Hansa Biopharma announced a PDUFA date of 19 December, indicating a standard rath...
Cicor reported H2 2025 sales of CHF 235.8m (2% vs. NDA and Bloomberg consensus), up 34.
Redeye has updated its estimates following Heliospectra’s Q4 2025 report.
Redeye is impressed by Safeture’s new partnership deal that was announced yesterday.
Although we see that Leaddesk’s ARR was negatively impacted by regulatory changes in some European c...
Nettoomsättningen uppgick till 0,6 MSEK (1,2) och övriga rörelseintäkter till 1,4 MSEK (2,6), vilket...
Seafire today announced the acquisition of Splendor Plant, the Nordic leader in wholesales plant nur...
Administer's Q4 results were mixed, with net sales declining slightly more than we had estimated, wh...
SynAct Pharma’s FY25 results reflect a year of solid execution, highlighted by the continued advance...
Efter den misslyckade satsningen mot elbilar återgår CTEK till kärnaffären: premiumladdare för lågvo...
Nettoomsättningen under det fjärde kvartalet 2025 uppgick till 6,4 MSEK (2,4), motsvarande en tillvä...
Acuvi redovisade ökad nettoomsättning och försämrat rörelseresultat i det fjärde kvartalet.
Redeye returns with positive estimate revisions on the back of AAC's Q4 report that fell short of ou...
CEO Michael-Robin Witt answers questions about the Q4 report and discusses other recent news with Vä...
Redeye comments on SynAct Pharma's directed share issue of gross cSEK52m.
Redeye returns with an update following AlzeCure’s Q4 2025 earnings release.
* Professor Hall comments on the XSTEM study results * In discussions with investigator-initiated st...
Redeye has updated its estimates and valuation following Physitrack’s Q4 2025 report.